Neoadjuvant therapy–associated malignant phenotype score predicts prognosis and highlights the roles of MIF signaling and DUXAP8 in ESCC
BackgroundEsophageal squamous cell carcinoma (ESCC) remains a major malignancy globally, and long-term survival outcomes remain poor despite advances in multimodal treatment strategies. Neoadjuvant therapy (NAT) has become the standard of care for resectable ESCC; however, substantial interpatient h...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2026-01-01
|
| シリーズ: | Frontiers in Immunology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1683349/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|